NCT01372761View on ClinicalTrials.gov

Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Obesity
Interventions
DRUG

ZGN-433

Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.

DRUG

Normal Saline

Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.

Trial Locations (1)

Unknown

Q-Pharm Clinics, Royal Brisbane and Women's Hospital, Brisbane

All Listed Sponsors
lead

Zafgen, Inc.

INDUSTRY

NCT01372761 - Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers | Biotech Hunter | Biotech Hunter